INTERFERON ALPHA 2B (IFN-α-2B) BUT NOT VITAMIN K2 SUPPLEMENTATION REDUCES LIVER CARCINOGENESIS IN MICE

VERA M; COMANZO C; ALVAREZ, MARÍA DE L.; LORENZETTI F; FERRETTI A; QUIROGA, ARIEL D.; LUCCI A; CEBALLOS MP; CARRILLO, MARÍA C.

Buenos Aires

Congreso; REUNIÓN DE SOCIEDADES DE BIOCIENCIAS 2020; 2020

SAIC, SAFIS, SAI

In HCC, IFN-α monotherapy is not satisfactory and its effects remaincontroversial. However, the combination of IFN-α with otheranti-cancer drugs, have had promising results. Vitamin K2 is presentin dairy products and has been recommended as a micronutrientsupplement in humans. Several studies have indicated that vitaminK2, may play a role in controlling the growth of HCC. Objective: toevaluate if the therapy of IFN-α-2b with vitamin K2 has a synergisticinhibitory action on DEN-induced carcinogenesis in mice. Methodsand Results: 14-day-old mice were injected ip with 25 mg/kg DEN(control group with tumor, CT). After 10 months mice were dividedinto 4 groups: CT; IFN: CT mice that received IFN-α-2b 6.5x105U/kg ip 5 times/week/3 weeks; VK2: CT mice that received vitamin K25 mg/kg ip 5 times/week/3 weeks; and IFN+VK2: CT mice whichreceived both drugs. Animals were euthanized after treatments andlivers were obtained. There were no differences in body and liver/body weight ratio between groups. CT mice treated with IFN-α-2bhad fewer tumors/liver and a trend to be smaller in size. VK2 andIFN+VK2 groups did not show differences respect to CT in numberand size tumors. Immunoblot analysis showed increase proapoptoticBax protein in IFN and decrease expression in IFN+VK2 groups(+51%* and -41%* respectively) respect to the CT group. PCNA proteinexpression showed a decrease (-60%*) in IFN group respect toCT. Finally, immunoblotting showed increase E-cadherin expressionin IFN and VK2 groups (+290%* and +145%* respectively) and nodifferences in N-cadherin protein expression between all the studiedgroups. (*p